荔枝核、茛芀花和罗浮粗叶木抗鸭乙肝病毒及护肝作用的实验性研究
|
摘要
为探讨中草药治疗乙型肝炎的新方法,我们用自己建立的广西麻鸭乙肝感染模型,对荔枝核、莨芀花和罗浮粗叶三种中药材的抗病毒及护肝作用进行了评价。结果发现,高剂量荔枝核水提物能明显抑制鸭乙型肝炎病毒的复制,而荔枝核醇提物和低剂量荔枝核水提物没有明显抑制鸭乙型肝炎病毒的作用；荔枝核水提物和醇提物降低AST和ALT活性均不明显。莨芀花醇提取物和罗浮粗叶木提取物均未见有抑制鸭乙肝病毒复制的作用。高剂量莨芀花醇提物对鸭乙肝病毒引起的肝损伤具有一定的保护作用。罗浮粗叶木提取物对鸭乙肝病毒引起的肝损伤保护作用不明显。
To explore new methods of herbal treatment of hepatitis B we used our own established infection model in ducks of Guangxi, and for litchi seed, Acanthus and the Rover coarse leaves of three Chinese herbal medicines, anti-virus and hepatoprotective effect was evaluated. The results found that high doses of Litchi aqueous extract can significantly inhibit duck hepatitis B virus, the the Litchi alcohol extract and the low dose of Litchi water extracts did not significantly inhibit the role of duck hepatitis B virus; aqueous extract of Litchi and The ethanol extract can not lower AST and ALT activities. While the Acanthus alcohol extract and Rover Lasianthus extracts showed no inhibition of DHBV replication. The high dose group of Acanthus ethanol extract on liver damage caused by DHBV seesms to have a protective effect. The Louvre Lasianthus extract has no protective effect to liver injury caused by the duck hepatitis B virus of the treatment group and blank control group, ALT activity, the difference was not significant.6AST activity also largely within the normal range, and AST activity in each group the difference was not significant, so it can not be judged for each treatment to reduce the efficacy of AST activity.
4, liver pathology examination found no significant differences in six groups of animals the severity of liver disease.
Conclusion:
High doses of Litchi aqueous extract can significantly inhibit duck hepatitis B virus, and the Litchi alcohol extract and the low dose of Litchi water extracts did not significantly inhibit the role of duck hepatitis B virus; not been able to clear the litchi seed aqueous extract and ethanol extracts can reduce AST and ALT activities in order to improve liver function, and whether or not to improve the role of liver pathological changes.
To explore new methods of herbal treatment of hepatitis B we used our own established infection model in ducks of Guangxi, and for litchi seed, Acanthus and the Rover coarse leaves of three Chinese herbal medicines, anti-virus and hepatoprotective effect was evaluated. The results found that high doses of Litchi aqueous extract can significantly inhibit duck hepatitis B virus, the the Litchi alcohol extract and the low dose of Litchi water extracts did not significantly inhibit the role of duck hepatitis B virus; aqueous extract of Litchi and The ethanol extract can not lower AST and ALT activities. While the Acanthus alcohol extract and Rover Lasianthus extracts showed no inhibition of DHBV replication. The high dose group of Acanthus ethanol extract on liver damage caused by DHBV seesms to have a protective effect. The Louvre Lasianthus extract has no protective effect to liver injury caused by the duck hepatitis B virus of the treatment group and blank control group, ALT activity, the difference was not significant.6AST activity also largely within the normal range, and AST activity in each group the difference was not significant, so it can not be judged for each treatment to reduce the efficacy of AST activity.
4, liver pathology examination found no significant differences in six groups of animals the severity of liver disease.
Conclusion:
High doses of Litchi aqueous extract can significantly inhibit duck hepatitis B virus, and the Litchi alcohol extract and the low dose of Litchi water extracts did not significantly inhibit the role of duck hepatitis B virus; not been able to clear the litchi seed aqueous extract and ethanol extracts can reduce AST and ALT activities in order to improve liver function, and whether or not to improve the role of liver pathological changes.
引文
1、World Health Organization. Hepqtitis B World Health Organization Factsheets N°2004(Revised october 2000)WHO Website.2006:http:// who.int/mediacentre/factsheets/fs204/en
2、王晓军,张荣珍,胡苑笙,等.我国病毒性肝炎流行现状研究[J]疾病监测,2004,19(8)：290-292
3、Hoofnagle Jay H, Di Bisceglie Adrian M. The treatment of chronic viral hepatitis. The New England Journal of Medicine.1997,336 (5):347-356
4、Kazuhiro Hanazaki. Antiviral Therapy for Chronic Hepatitis B:A Review. Targets-Inflammation & Allergy,2004,3,63-70
5、Otto S. Lin, Emmet B. Keefe.Current treatmemt stratigies for hepa-titis B and C, Annu. Rev. Med.200152:29-49
6、姚光弼.乙型和丙型肝炎药物的治疗进展[J].传染病信息,1999,12(1)：1
7、戴庆福,黄超林,赖东莲.血浆载脂蛋白E对糖尿病肾病的诊断价值[J].职业与健康,2000,16(3)：46-47
8、刘天灯,朱琳,丁秋霞.苦参素联合阿昔洛韦治疗慢性乙型肝炎28例[J].中西医结合肝病杂志,2001,11(1)：38-39
9、Ching-Lung Lai. Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B [J]. CID,2003,36:687-696
10、Papatheodoridis George V, Dimou Evangelini, Papadimitropoulos Vasilios. Nucleoside analogues for chronic hepatitis B:antiviral efficacy and viral resistance[J]. American Journal of Gastroent-erologym,2002,97:1618-1628.
11、Marion PL, Salazar FH, Winters MA, et al. Potent Efficacy of Entecavir(BMS-200475)in a Duck Model of Hepatitis B Virus Replication[J]. Antimicrob Agents Chemother,2002,46(1):82-88
12、Colonno RJ, GenovesiEV. MedinaL. et al. Long-term entecavir treatment results in sustained antiviral efficacy and prologed life span in the woodchuck model of chronic hepatitis infection [J].Journal of Infectious Diseases, 2001,184(10):1236-1245
13、陈压西,郭树华,齐珍元,等.叶下珠抗鸭乙型肝炎病毒的实验研究[J].重庆医科大学学报,2000,25(1)：39-40
14、曹慰祖,刘家琴,曹登云,等.安徽产叶下珠抗乙型肝炎病毒作用的临床研究[J].中国中药杂志,1998,23(3)：180-181
15、王传力,李春雨,毕国春,等.氧化苦参碱与α-干扰素治疗慢性乙肝疗效比较[J].人民军医,2001,44(10)：593-594
16、彭安邦,姚育红,谢黎明,等.苦参素治疗乙肝所致肝纤维化的临床观察[J].临床肝胆病杂志2004,20(5)：279-280
17、国家药典委员会编.中华人民共和国药典(一部)[M].北京：化学工业出版社,2000：196
18、郑民实,李桦,韩漪萍,等.100种中草药对乙型肝炎病毒表面抗原抑制作用的观察[J].中草药,1987,18(10)：27
19、杨燕,义祥辉,陈全斌,等.荔枝核对HbsAg和HBeAg的体外抑制作用[J].化工时刊,2001,7：24-26
20、徐庆,陈全斌,义祥辉,等.荔枝核提取物对HepG2.2.15细胞系HBsAg与HBeAg表达的影响[J].中国医院药学杂志,2004,24(7)：393-395
21、徐庆,宋芸娟,陈全斌,等.荔枝核黄酮类化合物对HepG2.2.15细胞系HBsAg与HBeAg表达及HBV-DNA含量的影响[J].第四军医大学学报,2004,25(20)：1862-1866
22、郭袭华,董长垣,高婧,等.一种从血清标本中快速提取HBV DNA万法的建立[J].武汉大学学报(医学版),2005,26(3)：333-335
23、袁伯俊,王治乔,主编.新编临床前安全性评价与实践[M].北京：军事医学科学出版社,1997：48
24、全国中草药汇编编写组.全国中草药汇编(下册)[M].北京：人民卫生出版社,1978：445
25、郭洁文,廖惠芳,潘竞锵,等.荔枝核皂苷对地塞米松致胰岛素抵抗糖尿病大鼠血糖血脂的影响[J].广东药学,2003,13(5)：32-35
26、Liu Y. Pharmaceutical composition containing a safe extracts of fruits and vegetables for the treating and preventing diabetes [P]. U. S. Patent.4985248,1991, (1):15
27、沈咪芳.荔枝核片治疗糖尿病的临床研究[J].中成药,1991,11：24
28、张禾,腾颢.丽仁降糖片希疗糖尿病45例疗效观察[J].中医杂志,1985,26(2)：40-41
29、郑琳颖,韩超,潘竞锵.荔枝核的化学、药理和临床研究概况[J].中医药学报,1998,(5)：51-53
30、杨燕军,梁北梅.荔枝核抗糖尿病有效部位总皂苷的含量测定[J].广东药学,2004,14(6)：13-15
31、屠鹏飞,罗青,郑俊华.荔枝核的化学成分研究[J].中草药,2002,33(4)：300-303
32、肖柳英,曾文铤,马佩球,等.荔枝核治疗慢性乙型肝炎48例[J]中医研究,2005,18(7)：21-23
33、陈压西,齐珍元,黄爱龙.碱性磷酸酶直接标记核酸探针检测血清中鸭乙肝病毒DNA方法的建立及应用[J].重庆医科大学学报,2003,28(2)：140-143
34、Wang Chi-Young J, Giambron Joseph J, Smith Bruce F. Comparison of cell culture systems for duck hepatitis B virus using SyBr green quantitative PCR[J]. Journal of Virological Methods,2002,106 (2):175-184
35、黄学忠.荧光定量PCR室内质控体系的概念及方法[J].国外医学临床生物化学与检验分册,2005,26(7)：478
36、康格非主编.临床生物化学和生物化学检验[M].第2版,北京：人民卫生出版社,1998：159-160
37、黄正明,杨新波,曹文斌,等.芹灵冲剂的保肝作用[J].中国医院药学杂志,2000,20(1)：5-7
38、郭海波,李婪.慢性乙型肝炎血清HBV DNA含量与HBeAg及ALT, AST的关系[J].中国现代医学杂志,2004,14(12)：72-74
39、沈秀娟,陈珊.乙型肝炎患者血清HBV DNA含量与肝功能部分指 标的关系[J].苏州医学院学报,2001,21(3)：314-315
40、黎新平.慢性乙型肝炎肝组织损伤与血清学指标相关性分析[J].浙江实用医学,2005,10(3)：149-173
41、骆抗先主编.乙型肝炎基础和临床[M].第1版,北京：人民卫生出版社,1997：115
42、Kundgen LR, Thoa C, Kock J, et al. Inhibition of duck hepatitis B virus replication by intrahepatic expression of an antiviral resistance gene [J]. J Mol Med,2002,80 (3):187-195
43、姚云清,唐霓,黄爱龙,等.乙型肝炎病毒DNA转染与鸭乙型肝炎病毒DNA感染原代鸭肝细胞对比研究[J].中华医学杂志,2001,81(19)：1157-1161
1. Zhang Q M, Zhang Y C, Sun S J. Tropical Marine Research(V)(热带海洋)[M].Beijing:Science Press,1997.
2. Lin P, Fu Q. Environmental Ecology and Economic Utilization of Mangroves in China(中国红树林环境生态及经济利用)[M].Beijing: High Education Press,1995.
3.Lin P. Medicinal plants of mangrove in China[J]. J Marine Drug,(海洋药物)1984,12(4)：45—51.
4.林鹏.中国红树林研究进展.厦门大学学报,2001,40(2)：592-603
5.彭兴,龙盛京.老鼠筋的化学成分和药理活性研究进展.国外医药(植物药分册),2004,19(6)：231-234
6.彭兴,龙盛京.老鼠簕提取成分的抗氧化活性[J].华西药学杂志,2006,21(1)：14-17
7.钱涯邻,孙沛毅,陈维名.乙肝Ⅱ号治疗慢性乙型病毒性肝炎时的抗氧自由基作用[J].中西医结合肝病杂志,2001,(4)：200.
8.彭黎明,王曾礼主编.细胞凋亡的基础和临床[M].北京：人民卫生出版社,2000.63.
9. Babu, B. H., Shylesh, B. S., Padikkala. Antioxdant and hepatoprotective effect of Acanthus ilicifolius. J India Fitoterapia,2001,72:272-7
10.中华人民共和国卫生部颁发.新药(西药)临床前研究指导原则汇编[S].1994,5：198
11.徐淑云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,1991,201
12.邓时贵,莫莉莉,区勇全,等.莪术油明胶微球制剂急性毒性实验[J].医药导报,2002,21(4)：200-202
13. Duflot A, Mehrotra R, Yu SZ, et al. Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology.1995 Jun,21 (6):1483-91
14.吴艳主编.药理学实验指导[M].第1版,北京：人民军医出版社,2003.
15.迪芬巴赫(Dieffenbach, C. W.),德维克斯勒(Dveksler, G. S.)著,黄培堂等译.PCR技术实验指南.北京：科学出版社,2000
16.郭龙华,董长垣,高婧,等.一种从血清标本中快速提取HBV DNA方法的建立[J].武汉大学学报(医学版),2005,26(3)：333-335
17. BIECHE I, OLIVI M, HELENE M, et al. Novel approach to quanti-tative polymerase chain reaction using real time detection:application to the detection of gene amplification in breast cancer [J]. Int J Cancer,1998,78:661-666
18.陈奇主编.中药药理研究方法学.第1版.北京：人民卫生出版社,1993.286-288
19.郑民实,章晋根,刘志勇.ELISA技术筛选200种中草药抗HBsAg的实验研究.微生物学杂志,1996,16(1)：1-4
20.《全国中草药汇编》编写组.全国中草药汇编(下册)[M].北京：人民卫生出版,1978：231
21. Aksornkoae S. Traditional uses of the Mangrove in Thailand. In. Mangrove Ecosystems of Asia and the Pacific. (Field. C. D. and A. J. Darmall. Eds.). Proceeding of the Research for Development Seminar. [R]Australian Committee for Mangrove Research. Townsville, Australia,1985-5-18
22.Agshikar NV, Naik VR, Abraham GJ, et al. Analgesic, anti-inflammatory activity of Acanthus ilicifolius Linn. Indian journal of Experimental Biology,1979,17:1257
23.陈冀胜.中国有毒植物[M].北京：科学出版社,1987：257
24.林鹏.中国红树林环境生态及经济利用[M].高等教育出版社,1995：19
25.林鹏.我国药用的红树植物[J].海洋药物,1984,3(4)：45
26.华南植物研究所.海南植物志[M].第二卷.北京,科学出版社,1974：180
27. Dienstag J. L, Popper H, Purccil R. H. The pathology of viral hepatitis types A and B in chimpanzees. Am. J. Patol.1976
28. Summers J, Smolec J. M, and Snyder R. A virus similar to human hepatitis B virus associatied with hepatitis and hepatoma in woodchucks. Proc. Nat. A cad. Sci. USA.1978,75:4533
29. Mason W. S., Seal G., Summers J. Virus of Pekin Ducks with Structural and Biological Relatedness to Human Hepatitis B Virus. Juournal of Virology.1980,3(36):829-836
30.陈压西等.重庆麻鸭乙肝动物模型的建立及应用.中西医结合肝病杂志.1994,4(3)：25-27
31.杨永刚,李壮,陈鸿珊.鸭乙型肝炎病毒实验感染后在外周血和肝脏中的动态[J].病毒学报,1988,4：259
32. Zuckerman AJ. Screening of antiviral drugs for hepadna virus infection in Pekin ducks:a review. J Virol Methods.1987 Aug,17(1-2):119-26. Review
33. Sherker A, et al. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks.Gastroenterology.1986 Oct,91(4):818-24
34. Tsiquaye K, et al. Suramin inhibits duck hepatitis B virus DNA polymerase activity. J Hepatol.1985,1(6):663-9
35. Uchiad T, et al. Occurence and ultrastructural localization of duck hepatitis B virus in the liver of duck after experimental infection. Hepatology,1987,7:29
36.刘伟.慢性乙型肝炎患者血清负荷与其肝组织炎症活动度的相 关性研究[J].临床肝胆病杂志,2002,2(18)：26
37.谈博,张奉学,操红缨等.鸭乙型肝炎病毒感染模型及其方法学研究进展[J].热带医学杂志,2005,5(1)：111-113,117
38.Freiman JS, Cossart YE.Natural duck hepatitis B virus infection in Australian [J]. Journal of Experimental Biology and Medical Science,1986,64(5):477-484
39.朱愉,多秀.实验动物的疾病模型[M].天津：天津科技翻译出版社,1997：386-388
40. Becker K., D. Pan and C. B. Whitely. Real-time quantitative polymerase chain reaction to assess gene transfer. Hum. Gene Ther, 1999,10:2559-2566
41.Higgis, J. A., etal.5'nuclease PCR assay to detect Yersinia pesits. J Clin Microbiol,1998,36:2284-2288
42. Bieche I., P. Oondy, etal. Real-time reverse transcription-PCR assay for future nagement of ERBB2-based clinical apolications. Clin. Chem,1999,45:1148-1156
43. Wang X. X. Li, etal. Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1 beta mRNA in ischemic brain tolerance.2000, Neurosci. Res,59(2): 238-46
44. Ozaki H et al. Nucleic Acids Res,1992; 20:5205
45. Tsiquaye K N, Collies P, Znckennan AJ. Antiviral activity of the polybasic anion, suramin and acylovir in hepadnavirus infection [J]. Antimicro Chemo,1986,18:223
46. Pratt DS, Kaplan MM. Evaluation of abnomal liver-enzyme results in asymptomatic patients[J]. N Engl J Med,2000, 342(177):1266-1277
47.康格非主编.临床生物化学和生物化学检验[M].第2版,北京：人民卫生出版社,1998：159-160
[1]罗献瑞.中国茜草科资料(三).热带亚热带植物学报[J].1993,2：1-17
[2]陈坤全,胡恩,陈清容.关于福建宁化“黄痧药”原植物的研究[J].海峡药学,2005,17(4)：103-104
[3]国家中医药管理局.中华本草[M].上海：上海科技出版社.1999.第六册,445
[4]Babu B.H., Shylesh B.S., Padikkala. Antioxdant and hepatoprotective effect of Acanthus ilicifolius. J India Fitoterapia,2001,72:272-7
[5]国家中医药管理局.中药、天然药物急性毒性研究技术指导原则.国家中医药管理局网站http://www.cde.org/cn/zdyz.do?method=largePage&id=2086
[6]徐叔云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,2002：227-231
[7]陈奇.中药药理研究方法学[M].北京：人民卫生出版社,1993：112-119
[8]吴艳.药理学实验指导[M].北京：人民军医出版社,2003.
[9]张忠泉,陈百泉.药理学实验指导[M].郑州大学出版社,2007,176-185
[10]邓时贵,莫莉莉,区勇全等.莪术油明胶微球制剂急性毒性实验[J].医药导报,2002,21(4)：200-202
[11]郭龙华,董长垣,高婧,等.一种从血清标本中快速提取HBV DNA万法的建立[J].武汉大学学报(医学版),2005,26(3)：333-335
[12]Mason WS, Seal G, Summer SJ. Virus of Peking ducks with structural and biological relatedness to human hepatitis B virus[J]. J Virol,1980,36:829-836.
[13]COVA L, ZOULIM F. Duck hepatitis B virus model in the study of hepatitis B virus [J]. Methods Mol Med,2004,96:261-268.
[14]HANTZ 0, ZOULIM F. Duck hepatitis B virus primary hepatocyte culture model [J]. Methods Mol Med,2004, 96:189-197.
[15]Gathuru JK, Koide F, Ragupathi G, et al. Identification of HBcAg as a potent carrier protein comparable to KLH for augumenting MUC1 antigenicity [J]. Vaccine,2005, 23:4727-4733.
[16]陈压西等.重庆麻鸭乙肝动物模型的建立及应用.中西医结合肝 病杂志.1994,4(3)：25-27
[17]张新全,黄正明,杨新波,等乙型肝炎病毒模型的方法学研究[J].解放军药学学报,2005,21(5)：360-363.
[18]牛巍,张继明,王文逸,等.复方药物ZL-1在鸭乙型肝炎病毒实验感染模型中抗病毒作用的研究[J].上海医学,2003,26(4)：234-238.
[19]Freiman JS, Cossart YE. Natural duck hepatitis B virus infection in Australian [J]. Journal of Experimental Biology and Medical Science,1986,64(5):477-484
[20]朱愉,多秀.实验动物的疾病模型[M].天津：天津科技翻译出版社,1997：386-388
[21]Becker K, D. Pan and C. B. Whitely. Real-time quantitative polymerase chain reaction to assess gene transfer. Hum. Gene Ther,1999,10:2559-2566
[22]Higgis, J. A., etal.5'nuclease PCR assay to detect Yersinia pesits. J Clin Microbiol,1998,36:2284-2288
[23]Bieche I., P. Oondy, etal. Real-time reverse transcription-PCR assay for future nagement of ERBB2-based clinical apolications. Clin. Chem,1999,45:1148-1156
[24]Wang X. X. Li, etal. Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1 beta mRNA in ischemic brain tolerance. 2000, Neurosci. Res,59(2):238-46
[25]0zaki H et al. Nucleic Acids Res,1992; 20:5205
[26]Yin JL, Shackel NA, Zekry A, et al. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or S YBR Green I [J].I m munol Cell Biol, 2001,79:213
[27]Holland PM, Abramson RD, Watson R, et al. Detection of specific polymerase chain reaction product by utilizing the 5'to 3'exonuclease activity of the thermos aquaticus DNA polymcrase. Proc Nat Aca Sci USA,1991,88:7276-7280
[28]Heid CA,et al. Real time quantitative PCR. Genome Res,1996,6(10):986-994
[29]Sen UE. A novel method for real time quantitative RT-PCR.Genome Res,1996,6(10):995-1001
[30]Pratt DS,Kaplan MM.Evaluation of abnomal liver-enzyme results in asymptomatic patients[J]. N Engl J Med,2000, 342(177):1266-1277
[31]康格非主编.临床生物化学和生物化学检验[M].第2版,北京：人民卫生出版社,1998：159-160
2、王晓军,张荣珍,胡苑笙,等.我国病毒性肝炎流行现状研究[J]疾病监测,2004,19(8)：290-292
3、Hoofnagle Jay H, Di Bisceglie Adrian M. The treatment of chronic viral hepatitis. The New England Journal of Medicine.1997,336 (5):347-356
4、Kazuhiro Hanazaki. Antiviral Therapy for Chronic Hepatitis B:A Review. Targets-Inflammation & Allergy,2004,3,63-70
5、Otto S. Lin, Emmet B. Keefe.Current treatmemt stratigies for hepa-titis B and C, Annu. Rev. Med.200152:29-49
6、姚光弼.乙型和丙型肝炎药物的治疗进展[J].传染病信息,1999,12(1)：1
7、戴庆福,黄超林,赖东莲.血浆载脂蛋白E对糖尿病肾病的诊断价值[J].职业与健康,2000,16(3)：46-47
8、刘天灯,朱琳,丁秋霞.苦参素联合阿昔洛韦治疗慢性乙型肝炎28例[J].中西医结合肝病杂志,2001,11(1)：38-39
9、Ching-Lung Lai. Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B [J]. CID,2003,36:687-696
10、Papatheodoridis George V, Dimou Evangelini, Papadimitropoulos Vasilios. Nucleoside analogues for chronic hepatitis B:antiviral efficacy and viral resistance[J]. American Journal of Gastroent-erologym,2002,97:1618-1628.
11、Marion PL, Salazar FH, Winters MA, et al. Potent Efficacy of Entecavir(BMS-200475)in a Duck Model of Hepatitis B Virus Replication[J]. Antimicrob Agents Chemother,2002,46(1):82-88
12、Colonno RJ, GenovesiEV. MedinaL. et al. Long-term entecavir treatment results in sustained antiviral efficacy and prologed life span in the woodchuck model of chronic hepatitis infection [J].Journal of Infectious Diseases, 2001,184(10):1236-1245
13、陈压西,郭树华,齐珍元,等.叶下珠抗鸭乙型肝炎病毒的实验研究[J].重庆医科大学学报,2000,25(1)：39-40
14、曹慰祖,刘家琴,曹登云,等.安徽产叶下珠抗乙型肝炎病毒作用的临床研究[J].中国中药杂志,1998,23(3)：180-181
15、王传力,李春雨,毕国春,等.氧化苦参碱与α-干扰素治疗慢性乙肝疗效比较[J].人民军医,2001,44(10)：593-594
16、彭安邦,姚育红,谢黎明,等.苦参素治疗乙肝所致肝纤维化的临床观察[J].临床肝胆病杂志2004,20(5)：279-280
17、国家药典委员会编.中华人民共和国药典(一部)[M].北京：化学工业出版社,2000：196
18、郑民实,李桦,韩漪萍,等.100种中草药对乙型肝炎病毒表面抗原抑制作用的观察[J].中草药,1987,18(10)：27
19、杨燕,义祥辉,陈全斌,等.荔枝核对HbsAg和HBeAg的体外抑制作用[J].化工时刊,2001,7：24-26
20、徐庆,陈全斌,义祥辉,等.荔枝核提取物对HepG2.2.15细胞系HBsAg与HBeAg表达的影响[J].中国医院药学杂志,2004,24(7)：393-395
21、徐庆,宋芸娟,陈全斌,等.荔枝核黄酮类化合物对HepG2.2.15细胞系HBsAg与HBeAg表达及HBV-DNA含量的影响[J].第四军医大学学报,2004,25(20)：1862-1866
22、郭袭华,董长垣,高婧,等.一种从血清标本中快速提取HBV DNA万法的建立[J].武汉大学学报(医学版),2005,26(3)：333-335
23、袁伯俊,王治乔,主编.新编临床前安全性评价与实践[M].北京：军事医学科学出版社,1997：48
24、全国中草药汇编编写组.全国中草药汇编(下册)[M].北京：人民卫生出版社,1978：445
25、郭洁文,廖惠芳,潘竞锵,等.荔枝核皂苷对地塞米松致胰岛素抵抗糖尿病大鼠血糖血脂的影响[J].广东药学,2003,13(5)：32-35
26、Liu Y. Pharmaceutical composition containing a safe extracts of fruits and vegetables for the treating and preventing diabetes [P]. U. S. Patent.4985248,1991, (1):15
27、沈咪芳.荔枝核片治疗糖尿病的临床研究[J].中成药,1991,11：24
28、张禾,腾颢.丽仁降糖片希疗糖尿病45例疗效观察[J].中医杂志,1985,26(2)：40-41
29、郑琳颖,韩超,潘竞锵.荔枝核的化学、药理和临床研究概况[J].中医药学报,1998,(5)：51-53
30、杨燕军,梁北梅.荔枝核抗糖尿病有效部位总皂苷的含量测定[J].广东药学,2004,14(6)：13-15
31、屠鹏飞,罗青,郑俊华.荔枝核的化学成分研究[J].中草药,2002,33(4)：300-303
32、肖柳英,曾文铤,马佩球,等.荔枝核治疗慢性乙型肝炎48例[J]中医研究,2005,18(7)：21-23
33、陈压西,齐珍元,黄爱龙.碱性磷酸酶直接标记核酸探针检测血清中鸭乙肝病毒DNA方法的建立及应用[J].重庆医科大学学报,2003,28(2)：140-143
34、Wang Chi-Young J, Giambron Joseph J, Smith Bruce F. Comparison of cell culture systems for duck hepatitis B virus using SyBr green quantitative PCR[J]. Journal of Virological Methods,2002,106 (2):175-184
35、黄学忠.荧光定量PCR室内质控体系的概念及方法[J].国外医学临床生物化学与检验分册,2005,26(7)：478
36、康格非主编.临床生物化学和生物化学检验[M].第2版,北京：人民卫生出版社,1998：159-160
37、黄正明,杨新波,曹文斌,等.芹灵冲剂的保肝作用[J].中国医院药学杂志,2000,20(1)：5-7
38、郭海波,李婪.慢性乙型肝炎血清HBV DNA含量与HBeAg及ALT, AST的关系[J].中国现代医学杂志,2004,14(12)：72-74
39、沈秀娟,陈珊.乙型肝炎患者血清HBV DNA含量与肝功能部分指 标的关系[J].苏州医学院学报,2001,21(3)：314-315
40、黎新平.慢性乙型肝炎肝组织损伤与血清学指标相关性分析[J].浙江实用医学,2005,10(3)：149-173
41、骆抗先主编.乙型肝炎基础和临床[M].第1版,北京：人民卫生出版社,1997：115
42、Kundgen LR, Thoa C, Kock J, et al. Inhibition of duck hepatitis B virus replication by intrahepatic expression of an antiviral resistance gene [J]. J Mol Med,2002,80 (3):187-195
43、姚云清,唐霓,黄爱龙,等.乙型肝炎病毒DNA转染与鸭乙型肝炎病毒DNA感染原代鸭肝细胞对比研究[J].中华医学杂志,2001,81(19)：1157-1161
1. Zhang Q M, Zhang Y C, Sun S J. Tropical Marine Research(V)(热带海洋)[M].Beijing:Science Press,1997.
2. Lin P, Fu Q. Environmental Ecology and Economic Utilization of Mangroves in China(中国红树林环境生态及经济利用)[M].Beijing: High Education Press,1995.
3.Lin P. Medicinal plants of mangrove in China[J]. J Marine Drug,(海洋药物)1984,12(4)：45—51.
4.林鹏.中国红树林研究进展.厦门大学学报,2001,40(2)：592-603
5.彭兴,龙盛京.老鼠筋的化学成分和药理活性研究进展.国外医药(植物药分册),2004,19(6)：231-234
6.彭兴,龙盛京.老鼠簕提取成分的抗氧化活性[J].华西药学杂志,2006,21(1)：14-17
7.钱涯邻,孙沛毅,陈维名.乙肝Ⅱ号治疗慢性乙型病毒性肝炎时的抗氧自由基作用[J].中西医结合肝病杂志,2001,(4)：200.
8.彭黎明,王曾礼主编.细胞凋亡的基础和临床[M].北京：人民卫生出版社,2000.63.
9. Babu, B. H., Shylesh, B. S., Padikkala. Antioxdant and hepatoprotective effect of Acanthus ilicifolius. J India Fitoterapia,2001,72:272-7
10.中华人民共和国卫生部颁发.新药(西药)临床前研究指导原则汇编[S].1994,5：198
11.徐淑云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,1991,201
12.邓时贵,莫莉莉,区勇全,等.莪术油明胶微球制剂急性毒性实验[J].医药导报,2002,21(4)：200-202
13. Duflot A, Mehrotra R, Yu SZ, et al. Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology.1995 Jun,21 (6):1483-91
14.吴艳主编.药理学实验指导[M].第1版,北京：人民军医出版社,2003.
15.迪芬巴赫(Dieffenbach, C. W.),德维克斯勒(Dveksler, G. S.)著,黄培堂等译.PCR技术实验指南.北京：科学出版社,2000
16.郭龙华,董长垣,高婧,等.一种从血清标本中快速提取HBV DNA方法的建立[J].武汉大学学报(医学版),2005,26(3)：333-335
17. BIECHE I, OLIVI M, HELENE M, et al. Novel approach to quanti-tative polymerase chain reaction using real time detection:application to the detection of gene amplification in breast cancer [J]. Int J Cancer,1998,78:661-666
18.陈奇主编.中药药理研究方法学.第1版.北京：人民卫生出版社,1993.286-288
19.郑民实,章晋根,刘志勇.ELISA技术筛选200种中草药抗HBsAg的实验研究.微生物学杂志,1996,16(1)：1-4
20.《全国中草药汇编》编写组.全国中草药汇编(下册)[M].北京：人民卫生出版,1978：231
21. Aksornkoae S. Traditional uses of the Mangrove in Thailand. In. Mangrove Ecosystems of Asia and the Pacific. (Field. C. D. and A. J. Darmall. Eds.). Proceeding of the Research for Development Seminar. [R]Australian Committee for Mangrove Research. Townsville, Australia,1985-5-18
22.Agshikar NV, Naik VR, Abraham GJ, et al. Analgesic, anti-inflammatory activity of Acanthus ilicifolius Linn. Indian journal of Experimental Biology,1979,17:1257
23.陈冀胜.中国有毒植物[M].北京：科学出版社,1987：257
24.林鹏.中国红树林环境生态及经济利用[M].高等教育出版社,1995：19
25.林鹏.我国药用的红树植物[J].海洋药物,1984,3(4)：45
26.华南植物研究所.海南植物志[M].第二卷.北京,科学出版社,1974：180
27. Dienstag J. L, Popper H, Purccil R. H. The pathology of viral hepatitis types A and B in chimpanzees. Am. J. Patol.1976
28. Summers J, Smolec J. M, and Snyder R. A virus similar to human hepatitis B virus associatied with hepatitis and hepatoma in woodchucks. Proc. Nat. A cad. Sci. USA.1978,75:4533
29. Mason W. S., Seal G., Summers J. Virus of Pekin Ducks with Structural and Biological Relatedness to Human Hepatitis B Virus. Juournal of Virology.1980,3(36):829-836
30.陈压西等.重庆麻鸭乙肝动物模型的建立及应用.中西医结合肝病杂志.1994,4(3)：25-27
31.杨永刚,李壮,陈鸿珊.鸭乙型肝炎病毒实验感染后在外周血和肝脏中的动态[J].病毒学报,1988,4：259
32. Zuckerman AJ. Screening of antiviral drugs for hepadna virus infection in Pekin ducks:a review. J Virol Methods.1987 Aug,17(1-2):119-26. Review
33. Sherker A, et al. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks.Gastroenterology.1986 Oct,91(4):818-24
34. Tsiquaye K, et al. Suramin inhibits duck hepatitis B virus DNA polymerase activity. J Hepatol.1985,1(6):663-9
35. Uchiad T, et al. Occurence and ultrastructural localization of duck hepatitis B virus in the liver of duck after experimental infection. Hepatology,1987,7:29
36.刘伟.慢性乙型肝炎患者血清负荷与其肝组织炎症活动度的相 关性研究[J].临床肝胆病杂志,2002,2(18)：26
37.谈博,张奉学,操红缨等.鸭乙型肝炎病毒感染模型及其方法学研究进展[J].热带医学杂志,2005,5(1)：111-113,117
38.Freiman JS, Cossart YE.Natural duck hepatitis B virus infection in Australian [J]. Journal of Experimental Biology and Medical Science,1986,64(5):477-484
39.朱愉,多秀.实验动物的疾病模型[M].天津：天津科技翻译出版社,1997：386-388
40. Becker K., D. Pan and C. B. Whitely. Real-time quantitative polymerase chain reaction to assess gene transfer. Hum. Gene Ther, 1999,10:2559-2566
41.Higgis, J. A., etal.5'nuclease PCR assay to detect Yersinia pesits. J Clin Microbiol,1998,36:2284-2288
42. Bieche I., P. Oondy, etal. Real-time reverse transcription-PCR assay for future nagement of ERBB2-based clinical apolications. Clin. Chem,1999,45:1148-1156
43. Wang X. X. Li, etal. Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1 beta mRNA in ischemic brain tolerance.2000, Neurosci. Res,59(2): 238-46
44. Ozaki H et al. Nucleic Acids Res,1992; 20:5205
45. Tsiquaye K N, Collies P, Znckennan AJ. Antiviral activity of the polybasic anion, suramin and acylovir in hepadnavirus infection [J]. Antimicro Chemo,1986,18:223
46. Pratt DS, Kaplan MM. Evaluation of abnomal liver-enzyme results in asymptomatic patients[J]. N Engl J Med,2000, 342(177):1266-1277
47.康格非主编.临床生物化学和生物化学检验[M].第2版,北京：人民卫生出版社,1998：159-160
[1]罗献瑞.中国茜草科资料(三).热带亚热带植物学报[J].1993,2：1-17
[2]陈坤全,胡恩,陈清容.关于福建宁化“黄痧药”原植物的研究[J].海峡药学,2005,17(4)：103-104
[3]国家中医药管理局.中华本草[M].上海：上海科技出版社.1999.第六册,445
[4]Babu B.H., Shylesh B.S., Padikkala. Antioxdant and hepatoprotective effect of Acanthus ilicifolius. J India Fitoterapia,2001,72:272-7
[5]国家中医药管理局.中药、天然药物急性毒性研究技术指导原则.国家中医药管理局网站http://www.cde.org/cn/zdyz.do?method=largePage&id=2086
[6]徐叔云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,2002：227-231
[7]陈奇.中药药理研究方法学[M].北京：人民卫生出版社,1993：112-119
[8]吴艳.药理学实验指导[M].北京：人民军医出版社,2003.
[9]张忠泉,陈百泉.药理学实验指导[M].郑州大学出版社,2007,176-185
[10]邓时贵,莫莉莉,区勇全等.莪术油明胶微球制剂急性毒性实验[J].医药导报,2002,21(4)：200-202
[11]郭龙华,董长垣,高婧,等.一种从血清标本中快速提取HBV DNA万法的建立[J].武汉大学学报(医学版),2005,26(3)：333-335
[12]Mason WS, Seal G, Summer SJ. Virus of Peking ducks with structural and biological relatedness to human hepatitis B virus[J]. J Virol,1980,36:829-836.
[13]COVA L, ZOULIM F. Duck hepatitis B virus model in the study of hepatitis B virus [J]. Methods Mol Med,2004,96:261-268.
[14]HANTZ 0, ZOULIM F. Duck hepatitis B virus primary hepatocyte culture model [J]. Methods Mol Med,2004, 96:189-197.
[15]Gathuru JK, Koide F, Ragupathi G, et al. Identification of HBcAg as a potent carrier protein comparable to KLH for augumenting MUC1 antigenicity [J]. Vaccine,2005, 23:4727-4733.
[16]陈压西等.重庆麻鸭乙肝动物模型的建立及应用.中西医结合肝 病杂志.1994,4(3)：25-27
[17]张新全,黄正明,杨新波,等乙型肝炎病毒模型的方法学研究[J].解放军药学学报,2005,21(5)：360-363.
[18]牛巍,张继明,王文逸,等.复方药物ZL-1在鸭乙型肝炎病毒实验感染模型中抗病毒作用的研究[J].上海医学,2003,26(4)：234-238.
[19]Freiman JS, Cossart YE. Natural duck hepatitis B virus infection in Australian [J]. Journal of Experimental Biology and Medical Science,1986,64(5):477-484
[20]朱愉,多秀.实验动物的疾病模型[M].天津：天津科技翻译出版社,1997：386-388
[21]Becker K, D. Pan and C. B. Whitely. Real-time quantitative polymerase chain reaction to assess gene transfer. Hum. Gene Ther,1999,10:2559-2566
[22]Higgis, J. A., etal.5'nuclease PCR assay to detect Yersinia pesits. J Clin Microbiol,1998,36:2284-2288
[23]Bieche I., P. Oondy, etal. Real-time reverse transcription-PCR assay for future nagement of ERBB2-based clinical apolications. Clin. Chem,1999,45:1148-1156
[24]Wang X. X. Li, etal. Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1 beta mRNA in ischemic brain tolerance. 2000, Neurosci. Res,59(2):238-46
[25]0zaki H et al. Nucleic Acids Res,1992; 20:5205
[26]Yin JL, Shackel NA, Zekry A, et al. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or S YBR Green I [J].I m munol Cell Biol, 2001,79:213
[27]Holland PM, Abramson RD, Watson R, et al. Detection of specific polymerase chain reaction product by utilizing the 5'to 3'exonuclease activity of the thermos aquaticus DNA polymcrase. Proc Nat Aca Sci USA,1991,88:7276-7280
[28]Heid CA,et al. Real time quantitative PCR. Genome Res,1996,6(10):986-994
[29]Sen UE. A novel method for real time quantitative RT-PCR.Genome Res,1996,6(10):995-1001
[30]Pratt DS,Kaplan MM.Evaluation of abnomal liver-enzyme results in asymptomatic patients[J]. N Engl J Med,2000, 342(177):1266-1277
[31]康格非主编.临床生物化学和生物化学检验[M].第2版,北京：人民卫生出版社,1998：159-160